For a post-Soliris world, Atlas-backed Q32 Bio outlines $46M next-gen complement play

Amber Tong

Long before Alexion kindled a renaissance of complement therapeutics with the introduction of the first anti-C5 antibody, Mike Holers — a longtime professor at the University …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

For a post-Soliris world, Atlas-backed Q32 Bio outlines $46M next-gen complement play

Amber Tong

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

For a post-Soliris world, At­las-backed Q32 Bio out­lines $46M next-gen com­ple­ment play

Amber Tong

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

For a post-Soliris world, Atlas-backed Q32 Bio outlines $46M next-gen complement play

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva